Stock comparison
Grifols
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GRFS
Grifols
Market cap
$6.93B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$43.67B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GRFS | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 59D | 75B | IDXX |
| Benjamin Graham | 54C | 80A | IDXX |
| Philip Fisher | 50C | 75B | IDXX |
| Peter Lynch | 44D | 71B | IDXX |
| Joel Greenblatt | 26F | 83C | IDXX |
| Charlie Munger | 44D | 87A | IDXX |
| Terry Smith | 47D | 84A | IDXX |
Side-by-side metrics
| Metric | GRFS | IDXX |
|---|---|---|
| Market cap | $6.93B | $43.67B |
| P/E (TTM) | 14.9x | 39.0x |
| EV/EBIT | 12.8x | 31.6x |
| ROIC (TTM) | 5.49% | 40.66% |
| Gross margin | 37.68% | 62.05% |
| Net margin | 5.58% | 24.63% |
| Revenue CAGR 5y | 10.02% | 7.56% |
| EPS CAGR 5y | 20.54% | 10.79% |
| Debt / Equity | 1.8x | 0.7x |
| Dividend yield | 1.65% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GRFS leads on
- Dividend yield1.65%vs 0.0%+100%
- P/E (TTM)14.9xvs 39.0x+62%
- EV/EBIT12.8xvs 31.6x+60%
- EPS CAGR 5y20.54%vs 10.79%+47%
IDXX leads on
- ROIC (TTM)40.66%vs 5.49%+86%
- Market cap$43.67Bvs $6.93B+84%
- Net margin24.63%vs 5.58%+77%
- Debt / Equity0.7xvs 1.8x+61%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.